Tag: Current Drug Safety
New Issues of various Bentham Science Journals
1. Mini-Reviews in Medicinal Chemistry, Vol: 18, Issue: 16
https://bit.ly/2qCXROI
2. Mini-Reviews in Medicinal Chemistry, Vol: 18, Issue: 17
https://bit.ly/2qBcaDd
3. Current Drug Targets, Vol: 19, Issue: 13
https://bit.ly/2QttYLL
4. Current Drug Metabolism, Vol: 19, Issue: 10
https://bit.ly/2qAdypw
5. Current Cancer Drug Targets, Vol: 18, Issue: 8
https://bit.ly/2z3e6sN
6. Current Pharmaceutical Analysis, Vol: 14, Issue: 6
https://bit.ly/2PNXYVE
7. The Natural Products Journal, Vol: 8, Issue: 3
https://bit.ly/2yYGJY6
8. Current Organocatalysis, Vol: 5, Issue: 2
https://bit.ly/2RKY65t
9. Current Drug Safety, Vol: 13, Issue: 3
https://bit.ly/2OvKMjC
10. Current Topics in Medicinal Chemistry, Vol: 18, Issue: 12
https://bit.ly/2D9ecSA
EDITOR’S CHOICE ARTICLE – Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature
Journal Name: Current Drug Safety
Author(s): Devis Benfaremo, Lucia Manfredi , Michele Maria Luchetti*, Armando Gabrielli.
Graphical Abstract:
Abstract:
Background: Immune checkpoint inhibitors are a new promising class of antitumor drugs that have been associated with a number of immune-related Adverse Events (AEs), including musculoskeletal and rheumatic disease.
Methods: We searched Medline reviewing reports of musculoskeletal and rheumatic AEs induced by immune checkpoint inhibitors.
Results: Several musculoskeletal and rheumatic AEs associated with immune checkpoint inhibitors treatment are reported in the literature. In particular, arthralgia and myalgia were the most common reported AEs, whereas the prevalence of arthritis, myositis and vasculitis is less characterized and mainly reported in case series and case reports. Other occasionally described AEs are sicca syndrome, polymyalgia rheumatica, systemic lupus erythematosus and sarcoidosis.
Conclusion: Newly induced musculoskeletal and rheumatic diseases are a frequent adverse event associated with immune checkpoint inhibitors treatment.
For more details, please visit: http://www.eurekaselect.com/161936/article
New Issue :: Current Drug Safety 13, Issue 1
Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
Articles from the journal Current Drug Safety 13, Issue 1:
- Glaucoma Drug Therapy in Pregnancy: Literature Review and Teratology Information Service (TIS) Case Series
- Comparative Randomized Crossover Clinical Study for the Evaluation of Erectile Dysfunction Medications Via Novel Pentagon System
- Knowledge, Practice and Attitudes Toward Pharmacovigilance and Adverse Drug Reactions Reporting Process Among Health Care Providers in Dammam, Saudi Arabia
- Fracture Risk Associated with Use of Antibiotics
- Effects of Vaccination Against the H1N1 Virus on BDNF and TNF-α Plasma Levels in Pregnant Women
- Generalized Intense Pruritus During Canagliflozin Treatment: Is it an Adverse Drug Reaction?
- A Case Report of Antitubercular Drugs Induced Exanthematous Reaction Complicated by Acute Onset Levofloxacin Induced Toxic Epidermal Necrolysis (TEN)
- Case Report: Severe Hematological, Muscle and Liver Toxicity Caused by Drugs and Artichoke Infusion Interaction in an Elderly Polymedicated Patient
- A Case of Inappropriate Self-Medication Compounded with Prescribing vis-à-vis Dispensing Errors and the Hazardous Consequence
- A Case of Capecitabine-induced Hyperammonemia in a Patient with Colon Cancer
- Itraconazole Induced Congestive Heart Failure, A Case Study
- Cyclophosphamide and/or Anthracyclines Induced Epiphora in Breast Cancer Patients: A Rare Side-effect
- Misoprostol-induced Acute Coronary Syndrome in a Premenopausal Woman: A Case Report with Literature Review
- Dolutegravir-Related Neurological Adverse Events: A Case Report of Successful Management with Therapeutic Drug Monitoring
For details on the articles, please visit this link :: https://bit.ly/2HS7AYs
SMi EVENT – 12th annual Parallel Trade!
SMi Group is proud to announce the return of Europe’s only Parallel Trade conference. Back for the 12th year, Parallel Trade returns to London on 6th-7th February 2018.
Over the years, the European Single market has allowed for pharmaceuticals to be imported and exported freely between member states without the permission of the manufacturers. However, with the arrival of Brexit and guidelines to immanently enforce the Falsified Medicines Directive (FMD) by 2019, the market for pharmaceutical parallel trade is changing.
Join us as we discuss the latest changes to regulation, their implementation and major court cases in intellectual property influencing distribution practices. We will also be exploring the safety of patients in relation to the surge in pharmaceutical E-commerce and ways in which currency fluctuations are likely to disrupt the flow of drugs to certain countries in the EU and beyond.
With huge interest from leaders in the field, we have worked closely with an expert panel of speakers to present an agenda that is shaping up to be the best Parallel Trade event. This year’s event will continue to lead with its unrivalled panel of experts bringing you the most insightful presentations from our confirmed Industry-leading speakers:
- Antonio Mendonca Alves, CEO, Md Pharma Sa
- Christopher Stothers, Partner, Arnold And Porter Kaye Scholer Llp
- Darragh O’loughlin, Secretary General, Irish Pharmacy Union
- Eric Noehrenberg, President, Noehrenberg International Policy Consulting
- Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara
- Farasat Bokhari, Senior Lecturer in Economics, Uea, University of East Anglia
- Felipe Florez-Arango, Head of Finance, Europe, Shire
- Frank Weissenfeldt, Senior Manager, Supplier Relations, Quintilesims
- Heinz Kobelt, Director European Affairs, European Association of Euro-Pharmaceutical Companies
- Ian Walker, Chairman, Epilepsy Action
- Janice Haigh, VP Pricing & Market Access, Parexel
- John Jolley, Managing Director, Pharmaconsult Global Ltd
- Mikas Rimantas, Business Development Director, Lexano
- Werner Berg, Partner, Baker & Mckenzie
Parallel Trade will address short term versus long term concerns of pharmaceutical manufacturers, regulators, parallel traders and patient associations.
The 2018 Parallel Trade conference will cover the important issues of:
- Maintaining the integrity of the supply chain
- Addressing recent developments concerning intellectual property and regulatory law
- Forecasting currency fluctuations across the single market and the affect this might have on drug shortages, prices and patient accessibility
- Exploring how Brexit will impact pharmaceutical trade and
market access in Europe - Providing an insight into current anti-trust investigations from industry leaders and the consequences this could have on pharmaceutical parallel trade
For more information visit the website at www.pharma-microbiology.com/BENTHAM or contact the team on email: kwilliams@smi-online.co.uk or call +44 (0) 207 827 6012
Journal: Current Drug Safety
EBook: Frontiers in Clinical Drug Research – Anti-Cancer Agents
Podcast: An Uncommon Case of Symptomatic Multiple Meningiomas with Bilateral Compressive Optic Neuropathy
Author(s): Chafik Keilani, Samir Abada.
For article details, visit: http://www.eurekaselect.com/152658/article
Subscribe our YouTube channel: http://bit.ly/1lr0czy
Wishing A Very Happy Birthday Dr. Seetal Dodd!
Dr. Seetal Dodd
Editor-in-Chief: Current Drug Safety
University of Melbourne
Geelong, 3220
Australia
New Issue ::: Current Drug Safety, 11 Issue 3
Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
Articles from the journal Current Drug Safety, Volume 11 Issue 3:
- Efficacy and Safety of Nonopioid Analgesics in Perioperative Pain Control
- Tramadol Induced QTc-Interval Prolongation: Prevalence, Clinical Factors and Correlation to Plasma Concentrations
- Impairment of Lung Function During Adjuvant Oxaliplatin Treatment in Patients with Colorectal Cancer: A Prospective Trial
- Ovarian Stimulation, Intrauterine Insemination, Multiple Pregnancy and Major Congenital Malformations: A Systematic Review and Meta- Analysis- The ART_Rev Study
- Very Low Dose Amitriptyline for Clozapine-Associated Sialorrhea
- When Nutraceuticals Reinforce Drugs Side Effects: A Case Report
- Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern
- Triamcinolone Acetonide and Bevacizumab Induced Raised Intraocular Pressure in An Elderly Male Diabetic Patient – A Case Report
- Steroid Induced Bilateral Avascular Necrosis of Head of Femur in an Adult Male Patient – A Case Report
For details on the articles, please visit this link :: http://bit.ly/2d8XofE
New Issue ::: Current Drug Safety
Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
Articles from the journal Current Drug Safety, Volume 11 Issue 2:
- The Challenge of Counterfeit Drugs: A Comprehensive Review on Prevalence, Detection and Preventive Measures
- Selective Serotonin Re-Uptake Inhibitors and Hyponatremia in Acutely Medically-Ill Inpatients
- Incidence of Adverse Drug Reactions in Indian Hospitals: A Systematic Review of Prospective Studies
- Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia
- A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia
- Perioperative Safety of Warfarin Therapy and Reversal
- A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients
- Patterns of Adverse Drug Reaction in the Medical Wards of a Teaching Hospital: A Prospective Observational Cohort Study
- Restless Legs Syndrome After Single Low Dose Quetiapine Administration
- Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction
- Different Omega-3 Formulations Yield to Diverse Clinical Response: A Case-Report
- Isoniazid Induced Metabolic Acidosis and Renal Dysfunction in an Elderly Patient with Chronic Renal Disease
- A Case of Hepatotoxicity Induced by Adulterated “Tiger King”, a Chinese Herbal Medicine Containing Sildenafil
- Lamotrigine Induced Whole Body Tics: A Case Report and Literature Review
- Griseofulvin and/or Terbinafine Induced Toxic Epidermal Necrolysis in an Adult Female Patient – A Case Report
For details on the articles, please visit this link :: http://bit.ly/1W8bAHJ
Bentham Press Release!
Emerging Sources Citation Index (ESCI) indexes Current Drug Safety
News release date: June 22, 2016
Dubai, UAE, June 22, 2016: Bentham Science journal Current Drug Safety has been accepted for inclusion in Emerging Sources Citation Index (ESCI) and will appear in WoS by August 2016.
Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety. For more information about the journal, visit here
As a new index in the Web of Science™ Core Collection, Emerging Sources Citation Index (ESCI) expands the citation universe and reflects the growing global body of science and scholarly activity. ESCI complements the highly selective indexes by providing earlier visibility for sources under evaluation as part of SCIE, SSCI, and AHCI’s rigorous journal selection process. Inclusion in ESCI provides greater discoverability which leads to measurable citations and more transparency in the selection process.
For further information on Emerging Sources Citation Index (ESCI), please visit: http://wokinfo.com/products_tools/multidisciplinary/esci/
Bentham Science 
You must be logged in to post a comment.